Details

Last Funding Type

Series C

Last Funding Money Raised

€12.40M

Industries

Biotechnology,Pharmaceutical,Therapeutics

Founded date

Jan 1, 2001

Number Of Employee

51 - 100

Operating Status

Active

TxCell, a spin off of Inserm (France's National Institute for Health and Medical Research) located in the technology park of Sophia Antipolis, near Nice in southern France, is developing cell-based immuno-therapies for the treatment of severe chronic inflammatory diseases with high medical need using its unique and proprietary technology platform based on the properties of Type 1 regulatory T lymphocytes (Tr1 cells).

The company has completed enrollment of a PhI/II study in refractory Crohn's disease patients and has reported first positive results. The company plans to initiate a PhIIb study in the same patient
population and bring a second product candidate into a PhI/II study in refractory rheumatoid arthritis patients.